We are pleased to announce that we have started a new company in China with Juno Therapeutics. The new company, JW Biotechnology, will leverage Juno’s immuno-oncology expertise and assets with WuXi’s R&D and manufacturing platform and local expertise to develop novel cell-based immunotherapies for patients with hematologic and solid organ cancers. James Li, M.D., formerly a Kleiner Perkins partner and General Manager of Amgen China, and a JW Biotechnology co-founder, has been appointed CEO of JW Biotechnology.
Over 2.5 million people in China die annually from cancer, making it imperative for us to find an effective structure to reach these patients. JW Biotechnology will collaborate broadly with Chinese medical communities and government regulators to develop cell therapies that will deliver cutting-edge cancer treatments to Chinese patients. These novel technologies offer a unique opportunity that holds the potential to save lives while transforming the treatment of cancer.